


# PRODUCT INFORMATION



## PNU 37883 (hydrochloride)

Item No. 44821

**CAS Registry No.:** 57568-80-6  
**Formal Name:** N-cyclohexyl-N'-tricyclo[3.3.1.1]dec-1-yl-4-morpholinecarboximidamide, monohydrochloride  
**Synonyms:** PNU 37883A, U-37883A  
**MF:** C<sub>21</sub>H<sub>35</sub>N<sub>3</sub>O • HCl  
**FW:** 382.0  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

PNU 37883 (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the PNU 37883 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. PNU 37883 (hydrochloride) is slightly soluble (0.1-1 mg/ml) in ethanol.

### Description

PNU 37883 is an inhibitor of ATP-sensitive potassium ( $K_{ATP}$ ) channels.<sup>1</sup> It inhibits sulfonylurea receptor 2B (SUR2B) linked to ATP-sensitive potassium channel  $K_{ir}6.2$  (SUR2B/ $K_{ir}6.2$ ) and SUR2B/ $K_{ir}6.1$  ( $IC_{50}$ s = 15.2 and 6  $\mu$ M, respectively) and SUR1/ $K_{ir}6.2$  and SUR2A/ $K_{ir}6.2$  to a lesser extent at 100  $\mu$ M. PNU 37883 (0.1 and 0.3  $\mu$ M) inhibits relaxation of isolated rat middle meningeal arteries induced by pinacidil (Item No. 15416), levcromakalim, or P1075 (Item No. 21849).<sup>2</sup> It increases kallikrein secretion from microdissected connecting tubules isolated from normotensive and spontaneously hypertensive rats.<sup>3</sup> PNU 37883 (15 mg/kg) increases sodium excretion and does not affect potassium excretion or glomerular filtration rate in saline-loaded rats.<sup>4</sup>

### References

1. Cui, Y., Tinker, A., and Clapp, L.H. Different molecular sites of action for the  $K_{ATP}$  channel inhibitors, PNU-99963 and PNU-37883A. *Br. J. Pharmacol.* **139**(1), 122-128 (2003).
2. Ploug, K.B., Boni, L.J., Baun, M., et al.  $K_{ATP}$  channel expression and pharmacological *in vivo* and *in vitro* studies of the  $K_{ATP}$  channel blocker PNU-37883A in rat middle meningeal arteries. *Br. J. Pharmacol.* **154**(1), 72-81 (2008).
3. Yamanaka, M., Hayashi, I., Fujita, T., et al. Potassium-induced increase in renal kallikrein secretion is attenuated in dissected renal connecting tubules of young spontaneously hypertensive rats. *Int. Immunopharmacol.* **2**(12-14), 1957-1964 (2002).
4. Ludens, J.H., Clark, M.A., and Lawson, J.A. Effects of a  $K^+$  channel blocker on glomerular filtration rate and electrolyte excretion in conscious rats. *J. Pharmacol. Exp. Ther.* **273**(3), 1375-1381 (1995).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/04/2026

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM